Compare Stocks: MDRX, SDGR, CERT, and GDRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CERT Certara	$7.96 -5.6%	$7.17	$4.45 ▼ $13.88	$1.29B	1.44	3.90 million shs	2.30 million shs
GDRX GoodRx	$3.44 -0.3%	$3.14	$1.77 ▼ $5.81	$1.18B	1.6	1.89 million shs	1.12 million shs
MDRX Veradigm	$4.90 -1.4%	$4.91	$3.00 ▼ $6.00	$599.27M	0.54	127,850 shs	352,029 shs
SDGR Schrodinger	$18.77 -4.8%	$16.53	$10.94 ▼ $23.02	$1.46B	1.63	1.16 million shs	914,434 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CERT Certara	0.00%	+5.38%	+12.25%	+60.88%	-26.50%
GDRX GoodRx	0.00%	-7.51%	+16.55%	+30.19%	-24.34%
MDRX Veradigm	0.00%	+1.43%	-3.31%	+4.63%	+2.47%
SDGR Schrodinger	0.00%	+12.05%	+31.66%	+48.20%	-3.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CERT Certara	$7.96 -5.6%	$7.17	$4.45 ▼ $13.88	$1.29B	1.44	3.90 million shs	2.30 million shs
GDRX GoodRx	$3.44 -0.3%	$3.14	$1.77 ▼ $5.81	$1.18B	1.6	1.89 million shs	1.12 million shs
MDRX Veradigm	$4.90 -1.4%	$4.91	$3.00 ▼ $6.00	$599.27M	0.54	127,850 shs	352,029 shs
SDGR Schrodinger	$18.77 -4.8%	$16.53	$10.94 ▼ $23.02	$1.46B	1.63	1.16 million shs	914,434 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CERT Certara	0.00%	+5.38%	+12.25%	+60.88%	-26.50%
GDRX GoodRx	0.00%	-7.51%	+16.55%	+30.19%	-24.34%
MDRX Veradigm	0.00%	+1.43%	-3.31%	+4.63%	+2.47%
SDGR Schrodinger	0.00%	+12.05%	+31.66%	+48.20%	-3.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CERT Certara	2.42	Hold	$8.28	4.06% Upside
GDRX GoodRx	2.08	Hold	$4.23	22.71% Upside
MDRX Veradigm	0.00	N/A	N/A	N/A
SDGR Schrodinger	2.29	Hold	$20.50	9.22% Upside

Current Analyst Ratings Breakdown

Latest MDRX, SDGR, CERT, and GDRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2026	GDRX GoodRx	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Underweight	$3.00 ➝ $4.00
8/14/2026	SDGR Schrodinger	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$13.00 ➝ $19.00
8/14/2026	SDGR Schrodinger	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$13.00 ➝ $19.00
8/13/2026	GDRX GoodRx	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$2.50 ➝ $3.75
8/12/2026	SDGR Schrodinger	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	GDRX GoodRx	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$4.00 ➝ $5.00
8/11/2026	GDRX GoodRx	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$4.00 ➝ $5.00
8/7/2026	GDRX GoodRx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
8/7/2026	GDRX GoodRx	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$4.00
8/7/2026	GDRX GoodRx	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$3.50 ➝ $5.00
8/6/2026	GDRX GoodRx	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$5.00

(Data available from 8/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CERT Certara	$421.75M	2.88	$0.71 per share	11.14	$6.67 per share	1.19
GDRX GoodRx	$785.23M	1.50	$0.40 per share	8.62	$1.81 per share	1.90
MDRX Veradigm	$1.53B	0.39	N/A	N/A	N/A	∞
SDGR Schrodinger	$259.04M	5.35	N/A	N/A	$4.94 per share	3.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CERT Certara	-$1.60M	-$0.45	N/A	28.41	N/A	-16.75%	3.86%	2.65%	11/5/2026 (Estimated)
GDRX GoodRx	$30.44M	$0.04	86.15	17.23	1.72	2.07%	7.22%	2.53%	11/3/2026 (Estimated)
MDRX Veradigm	N/A	N/A	23.25	N/A	N/A	N/A	N/A	N/A	N/A
SDGR Schrodinger	-$103.26M	-$0.74	N/A	N/A	N/A	-20.98%	-16.37%	-8.19%	11/4/2026 (Estimated)

Latest MDRX, SDGR, CERT, and GDRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2026	Q2 2026	GDRX GoodRx	$0.0797	$0.08	+$0.0003	$0.02	$193.23 million	$200.41 million
8/5/2026	Q2 2026	SDGR Schrodinger	-$0.4145	$0.08	+$0.4945	$0.08	$47.19 million	$58.89 million
8/4/2026	Q2 2026	CERT Certara	$0.0893	$0.08	-$0.0093	-$0.36	$98.09 million	$93.27 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CERT Certara	N/A	N/A	N/A	N/A	N/A
GDRX GoodRx	N/A	N/A	N/A	N/A	N/A
MDRX Veradigm	N/A	N/A	N/A	N/A	N/A
SDGR Schrodinger	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CERT Certara	0.30	2.55	2.55
GDRX GoodRx	0.74	1.38	1.38
MDRX Veradigm	N/A	N/A	N/A
SDGR Schrodinger	N/A	2.71	2.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CERT Certara	73.96%
GDRX GoodRx	63.77%
MDRX Veradigm	N/A
SDGR Schrodinger	79.05%

Insider Ownership

Company	Insider Ownership
CERT Certara	1.08%
GDRX GoodRx	5.87%
MDRX Veradigm	2.29%
SDGR Schrodinger	10.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CERT Certara	1,576	152.54 million	150.89 million	Optionable
GDRX GoodRx	950	342.57 million	322.47 million	Optionable
MDRX Veradigm	8,000	122.30 million	105.18 million	No Data
SDGR Schrodinger	790	73.83 million	66.37 million	Optionable

MDRX, SDGR, CERT, and GDRX Headlines

Recent News About These Companies

Schrödinger: The Software Business Is Stronger Than It Looks

August 22 at 1:22 AM | seekingalpha.com

Tejara Capital Ltd Takes $4.55 Million Position in Schrodinger, Inc. $SDGR

August 21 at 6:00 AM | marketbeat.com

Schrodinger (NASDAQ:SDGR) Trading 10.4% Higher - What's Next?

August 19, 2026 | marketbeat.com

4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma

August 17, 2026 | zacks.com

Schrodinger Inc (SDGR) Stock Down 4.8% -- Now Undervalued? GF Score: 73/100

August 14, 2026 | gurufocus.com

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

August 14, 2026 | businesswire.com

Schrödinger (SDGR) Q2 2026 Earnings Call Transcript

August 13, 2026 | fool.com

Quantinno Capital Management LP Buys Shares of 174,095 Schrodinger, Inc. $SDGR

August 12, 2026 | marketbeat.com

Dimensional Fund Advisors LP Cuts Holdings in Schrodinger, Inc. $SDGR

August 10, 2026 | marketbeat.com

Schrodinger (NASDAQ:SDGR) Raised to "Hold" at Wall Street Zen

August 8, 2026 | marketbeat.com

Morgan Stanley Keeps Their Hold Rating on Schrodinger (SDGR)

August 7, 2026 | theglobeandmail.com

BMO Capital Reaffirms Their Buy Rating on Schrodinger (SDGR)

August 7, 2026 | theglobeandmail.com

Schrodinger, Inc. Earnings Call Highlights Growth Amid Shift

August 6, 2026 | tipranks.com

Schrödinger, Inc. 2026 Q2 - Results - Earnings Call Presentation

August 6, 2026 | seekingalpha.com

Schrödinger, Inc. (SDGR) Q2 2026 Earnings Call Transcript

August 6, 2026 | seekingalpha.com

Schrödinger (SDGR) Is Up 8.5% After AI Co‑Scientist Deal With BMS And Q2 Profitability Shift – Has The Bull Case Changed?

August 6, 2026 | finance.yahoo.com

Schrodinger Q2 Earnings Call Highlights

August 6, 2026 | marketbeat.com

Flash résultats (SDGR) : Schrodinger, Inc. publie un chiffre d'affaires de 58,9 millions de dollars au deuxième trimestre

August 5, 2026 | zonebourse.comZ

Schrodinger, Inc. (SDGR) Q2 Earnings and Revenues Top Estimates

August 5, 2026 | zacks.com

Schrodinger (NASDAQ:SDGR) Announces Quarterly Earnings Results

August 5, 2026 | marketbeat.com

Schrödinger Reports Second Quarter 2026 Financial Results

August 5, 2026 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MDRX, SDGR, CERT, and GDRX Company Descriptions

Certara NASDAQ:CERT

$7.96 -0.47 (-5.58%)

Closing price 04:00 PM Eastern

Extended Trading

$8.03 +0.07 (+0.87%)

As of 05:41 PM Eastern

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

GoodRx NASDAQ:GDRX

$3.44 -0.01 (-0.29%)

Closing price 04:00 PM Eastern

Extended Trading

$3.44 +0.00 (+0.15%)

As of 07:05 PM Eastern

GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.

Veradigm NASDAQ:MDRX

$4.90 -0.07 (-1.41%)

As of 02:45 PM Eastern

Veradigm Inc., a healthcare technology company, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions. The company operates through two segments, Hospitals and Large Physician Practices, and Veradigm. The Hospitals and Large Physician Practices segment provides integrated clinical and financial management solutions, which primarily include EHR-related software; and related installation, support and maintenance, outsourcing, private cloud hosting, and revenue cycle management services. The Veradigm segment offers payer and life sciences solutions, which are primarily targeted at payers, life sciences companies, and other healthcare stakeholders; and software applications for patient engagement and EHR software to single-specialty, and small and mid-sized physician practices, including related clinical, financial, administrative, and operational solutions. Its solutions enable clients to transition, analyze, and coordinate care, and enhance the healthcare delivery across the care community. The company serves physicians, hospitals, governments and militaries, health systems, health plans, life-sciences companies, retail clinics, surgery centers, retail pharmacies, pharmacy benefit managers, insurance companies, employer wellness clinics, consumers, lab companies, urgent care facilities, and venture capital firms, as well as post-acute organizations, such as home health and hospice agencies. The company was formerly known as Allscripts Healthcare Solutions, Inc. and changed its name to Veradigm Inc. in January 2023. Veradigm Inc. was founded in 1986 and is headquartered in Chicago, Illinois.

Schrodinger NASDAQ:SDGR

$18.77 -0.94 (-4.77%)

Closing price 04:00 PM Eastern

Extended Trading

$18.89 +0.12 (+0.63%)

As of 07:05 PM Eastern

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MDRX, SDGR, CERT, and GDRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MDRX, SDGR, CERT, and GDRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MDRX, SDGR, CERT, and GDRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MDRX, SDGR, CERT, and GDRX Company Descriptions

Certara NASDAQ:CERT

GoodRx NASDAQ:GDRX

Veradigm NASDAQ:MDRX

Schrodinger NASDAQ:SDGR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MDRX, SDGR, CERT, and GDRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MDRX, SDGR, CERT, and GDRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MDRX, SDGR, CERT, and GDRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MDRX, SDGR, CERT, and GDRX Company Descriptions

Certara NASDAQ:CERT

GoodRx NASDAQ:GDRX

Veradigm NASDAQ:MDRX

Schrodinger NASDAQ:SDGR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools